Health ❯ Diabetes ❯ Type 2 Diabetes

Medications

GLP-1 Receptor Agonists Ozempic Semaglutide Mounjaro Tirzepatide Clinical Trials Extensior FDA Approval Ozempic and Mounjaro Orforglipron Sémaglutide Hormonal Treatments GLP-1 Drugs Weight Management GLP-1 Agonists Incretins GLP-1 Tirzepatida GLP-1 Injections Retatrutide Insulin Production Semaglutida

Lilly Urges Recall After Finding New Impurity in Compounded Tirzepatide With B12

The warning focuses on mass-marketed 'personalized' versions sold outside FDA review.

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

GLP-1 Drugs Linked to Lower Five-Year Death Risk in Colon Cancer, UCSD Study Finds

Resalis’ miR-22 Antisense Shows Durable Fat Loss in Animals as Phase 1 Trial Continues

GLP-1 Drugs Linked to Lower Overall Cancer Risk in JAMA Oncology Analysis